Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Equities researchers at Cantor Fitzgerald raised their FY2017 EPS estimates for shares of Endo International PLC in a research note issued on Sunday. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of $3.64 for the year, up from their prior estimate of $3.35. Cantor Fitzgerald has a “Neutral” rating and a $7.00 price target on the stock. Cantor Fitzgerald also issued estimates for Endo International PLC’s FY2018 earnings at $3.11 EPS.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. The company had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. During the same period last year, the business earned $1.01 EPS. Endo International PLC’s quarterly revenue was down 11.0% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: “Research Analysts Set Expectations for Endo International PLC’s FY2017 Earnings (ENDP)” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/11/16/research-analysts-set-expectations-for-endo-international-plcs-fy2017-earnings-endp.html.
Endo International PLC (ENDP) opened at $7.02 on Wednesday. Endo International PLC has a twelve month low of $5.77 and a twelve month high of $18.05. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. The stock has a market capitalization of $1,560.00, a price-to-earnings ratio of 1.38 and a beta of 0.53.
A number of institutional investors and hedge funds have recently made changes to their positions in ENDP. James Investment Research Inc. purchased a new stake in Endo International PLC in the 2nd quarter worth about $113,000. Blair William & Co. IL purchased a new stake in Endo International PLC in the 2nd quarter worth about $126,000. LMR Partners LLP purchased a new stake in Endo International PLC in the 3rd quarter worth about $148,000. Point View Wealth Management Inc. increased its holdings in Endo International PLC by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after acquiring an additional 1,900 shares during the last quarter. Finally, Riverhead Capital Management LLC increased its holdings in Endo International PLC by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after acquiring an additional 5,887 shares during the last quarter. 90.50% of the stock is owned by institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.